Drake L, Prendergast M, Maher R, Breneman D, Korman N, Satoi Y, Beusterien K M, Lawrence I
Oklahoma University Health Science Center, Oklahoma City, USA.
J Am Acad Dermatol. 2001 Jan;44(1 Suppl):S65-72. doi: 10.1067/mjd.2001.109814.
Atopic dermatitis can have detrimental effects on health-related quality of life (QOL).
Our purpose was to examine the QOL impact of tacrolimus ointment in patients with atopic dermatitis.
The Dermatology Life Quality Index (DLQI), Children's DLQI (CDLQI), and Toddler QOL Survey were used to assess QOL in adults (16 years or older), children (5-15 years), and toddlers (2-4 years) enrolled in 12-week, randomized, double-blind studies comparing two concentrations of tacrolimus ointment (0.03% and 0.1%) versus vehicle ointment for treatment of atopic dermatitis. QOL was assessed at baseline, week 3, and week 12/early discontinuation.
Of the 985 patients enrolled, 91.5% had evaluable QOL data. Among adults, both tacrolimus ointment groups experienced improved QOL relative to the vehicle control group for all QOL scales (P<.001). Among children and toddlers, both tacrolimus ointment groups demonstrated significant QOL improvements relative to the vehicle control group (P<.05) for all but the Personal Relationships scale in the 0.03% tacrolimus ointment group among children.
Tacrolimus ointment is associated with significant QOL benefits in adults, children, and toddlers with atopic dermatitis.
特应性皮炎会对健康相关生活质量（QOL）产生不利影响。
我们的目的是研究他克莫司软膏对特应性皮炎患者生活质量的影响。
皮肤病生活质量指数（DLQI）、儿童DLQI（CDLQI）和幼儿生活质量调查用于评估参与为期12周的随机双盲研究的成年人（16岁及以上）、儿童（5 - 15岁）和幼儿（2 - 4岁）的生活质量。该研究比较了两种浓度的他克莫司软膏（0.03%和0.1%）与赋形剂软膏治疗特应性皮炎的效果。在基线、第3周和第12周/提前停药时评估生活质量。
在纳入的985例患者中，91.5%有可评估的生活质量数据。在成年人中，相对于赋形剂对照组，两个他克莫司软膏组在所有生活质量量表上的生活质量均有所改善（P <.001）。在儿童和幼儿中，相对于赋形剂对照组，两个他克莫司软膏组在除儿童0.03%他克莫司软膏组的人际关系量表外的所有量表上均显示出生活质量的显著改善（P <.05）。
他克莫司软膏对患有特应性皮炎的成年人、儿童和幼儿的生活质量有显著益处。
